What percent of ovarian cancer is platinum resistant?
Standard treatment for ovarian cancer is platinum-based chemotherapy; however, 15% to 30% of patients with ovarian cancer have primary platinum-resistant or refractory disease.
What does platinum resistant ovarian cancer mean?
“Platinum resistant” ovarian cancer was historically defined as disease recurrence within 6months of completion of first-line platinum-based chemotherapy, although this is now more broadly applied to also include patients progressing within 6months after multiple lines of chemotherapy.
What is the difference between platinum resistant and platinum sensitive?
Patients with a PFI of six months or longer are considered to have chemotherapy-sensitive disease (often also termed “platinum-sensitive”). Patients with a PFI of less than six months are considered to have chemotherapy-resistant disease (often also termed “platinum-resistant”).
What is refractory ovarian cancer?
More recently, a widely accepted categorization particularly for the design of clinical trials defines ‘platinum refractory’ as disease progressing during therapy or within 4 weeks after the last dose; ‘platinum resistant’ as disease progressing within 6 months of platinum-based therapy; ‘partially platinum sensitive’ …
What is the mortality rate for ovarian cancer?
Ovarian cancer survival rates are much lower than other cancers that affect women. The relative five-year survival rate for ovarian cancer is 48% percent. Women diagnosed at an early stage—before the cancer has spread—have a much higher five-year survival rate than those diagnosed at a later stage.
How can you prevent ovarian cancer relapse?
New research in mice identifies a compound that prevents ovarian cancer recurrence by eradicating the cancer stem-like cells that conventional chemotherapy leaves behind. Share on Pinterest New findings could change the face of ovarian cancer treatment.
Why is platinum used in cancer treatment?
The platinum compounds are largely used in the treatment of lung, breast, ovarian, and colon cancers. The chemotherapeutic mechanism of platinum compounds is typical of DNA-binding alkylating agents. If the DNA damage exceeds the ability of the cell to repair, the cell undergoes apoptotic cell death.
Can recurrent ovarian cancer be cured?
Recurrent ovarian cancer is a lethal disease, and few patients can be cured. Although most patients receive standardized surgery and chemotherapy, the status of recurrent disease is heterogeneous. The site of recurrence and the survival intervals after recurrence are also widely distributed.
What does platinum sensitive mean?
Some cancers that respond to treatment but then come back after a certain period may also be considered platinum sensitive. For example, ovarian cancer that comes back 6 or more months after platinum-based treatment is considered platinum sensitive.
What is platinum free interval?
The platinum-free interval (PFI)—defined as the time between the last cycle of platinum and evidence of disease progression—is an important predictor of outcome and response to further treatment.
What does platinum refractory mean?
For example, “platinum-refractory” is defined as cases in which the disease progresses during platinum-based therapy; “platinum-resistant” is defined as cases in which the disease relapses within 6 months after the end of platinum treatment; and “platinum-sensitive” is defined as cases in which the disease relapses at …
What is the best treatment for recurrent ovarian cancer?
The main treatment for recurrent ovarian cancer is anti cancer drug treatment (chemotherapy). You also might have surgery or targeted cancer drugs.
Can PARP inhibitors cure ovarian cancer?
Following the results of the SOLO-1 trial, maintenance PARP inhibitors have become the standard of care for patients with BRCA-mutated ovarian cancer but overall survival data are needed to confirm their potentially curative benefit.
What is second line treatment for ovarian cancer?
Re-induction treatment with a platinum-based combination therapy with paclitaxel or gemcitabine is now considered to be the standard second-line treatment for patients with platinum-sensitive ovarian cancer.